PPL was established in 2013 after it obtained an exclusive license in non-oncology fields for patents relating to the use and know-how of the Antennapedia protein (ANTP) transduction technology developed by Trojantec.  Patents were granted in the USA, Australia, Israel and New Zealand and applied for in Japan and Canada.  PPL’s leadership has a proven track record in successful drug development and plans to use this technology and other cell permeable peptide platforms to develop candidates that can normalize abnormal gene expression and function to improve medical outcomes in a variety of diseases with high medical need.